Trial reportPhysiological genomics2016
Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study.
Trial report in Physiological genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study.PLoS medicine · 2024Trial
- Lessons from KEEPS: the Kronos Early Estrogen Prevention Study.Climacteric : the journal of the International Menopause Society · 2021Trial
- Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study.Menopause (New York, N.Y.) · 2020Trial
- Specific cell-derived microvesicles: Linking endothelial function to carotid artery intima-media thickness in low cardiovascular risk menopausal women.Atherosclerosis · 2016Trial
- Differential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS.Climacteric : the journal of the International Menopause Society · 2016Trial
- Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.European heart journal · 2021Article
- Advances in Precision Health and Emerging Diagnostics for Women.Journal of clinical medicine · 2019Review
- The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?Menopause (New York, N.Y.) · 2019Review
- Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study.Menopause (New York, N.Y.) · 2019Article
- Cognitive Changes with Reproductive Aging, Perimenopause, and Menopause.Obstetrics and gynecology clinics of North America · 2018Review
- Sex Steroids and Incident Cardiovascular Disease in Post-Menopausal Women: New Perspective on an Old Controversy.Journal of the American College of Cardiology · 2018Article
- An update on hormone therapy in postmenopausal women: mini-review for the basic scientist.American journal of physiology. Heart and circulatory physiology · 2017Review
- A theory of eu-estrogenemia: a unifying concept.Menopause (New York, N.Y.) · 2017Review
- Sex hormone therapy and progression of cardiovascular disease in menopausal women.Clinical science (London, England : 1979) · 2016Review
- Sex-Specific Physiology and Cardiovascular Disease.Advances in experimental medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
Abstract
Prior to the initiation of menopausal hormone treatment (MHT), genetic variations in the innate immunity pathway were found to be associated with carotid artery intima-medial thickness (CIMT) and coronary arterial calcification (CAC) in women (n = 606) enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Whether MHT might affect these associations is unknown. The association of treatment outcomes with variation in the same 764 candidate genes was evaluated in the same KEEPS participants 4 yr after randomization to either oral conjugated equine estrogens (0.45 mg/day), transdermal 17β-estradiol (50 μg/day), each with progesterone (200 mg/day) for 12 days each month, or placebo pills and patch. Twenty SNPs within the innate immunity pathway most related with CIMT after 4 yr were not among those associated with CIMT prior to MHT. In 403 women who completed the study in their assigned treatment group, single nucleotide polymorphisms (SNPs) within the innate immunity pathway were found to alter the treatment effect on 4 yr change in CIMT (i.e., significant interaction between treatment and genetic variation in the innate immunity pathway; P < 0.001). No SNPs by treatment effects were observed with changes of CAC >5 Agatston units after 4 yr. Results of this study suggest that hormonal status may interact with genetic variants to influence cardiovascular phenotypes, specifically, the pharmacogenomic effects within the innate immunity pathway for CIMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.